Xenon Pharmaceuticals Inc.
XENE
Clasificación en acciones
#4533
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Precio por acción
$35.08
Última sincronización: 2026-10-19
Capitalización bursátil
$3.40B
Cambio (1 día)
4.75%
Cambio (1 año)
-19.24%
País
CA
Comercio Xenon Pharmaceuticals Inc. (XENE)
Categoría
Healthcare
Ganancias de Xenon Pharmaceuticals Inc. (XENE)
Ganancias en Jun 2026 TTM: $-411.14M
Secondo gli ultimi rapporti finanziari di Xenon Pharmaceuticals Inc., gli utili attuali della società sono $-411.14M. Nel 2023, la società ha registrato un utile di $-182.69M, una disminución en comparación con agli utili del 2022, che erano di $-125.26M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Xenon Pharmaceuticals Inc. desde 2011 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-411.14M | 72.44% |
| 2024 | $-238.42M | 30.51% |
| 2023 | $-182.69M | 45.85% |
| 2022 | $-125.26M | 58.78% |
| 2021 | $-78.89M | 171.15% |
| 2020 | $-29.09M | -30.09% |
| 2019 | $-41.62M | 20.64% |
| 2018 | $-34.50M | 12.35% |
| 2017 | $-30.70M | 33.51% |
| 2016 | $-23.00M | 45.99% |
| 2015 | $-15.75M | -221.00% |
| 2014 | $13.02M | 8.19% |
| 2013 | $12.03M | -379.75% |
| 2012 | $-4.30M | -64.13% |
| 2011 | $-11.99M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,383.01% |
US
|
|
| $-3.09B | 650.85% |
US
|
|
| $-4.02B | 876.85% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -574.45% |
NL
|
